1-Oleoyl lysophosphatidic acid sodium (GMP)
1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates LPA1 and LPA2, thereby triggering calcium mobilization, NFATc1 translocation, Rho/ROCK activation, Smad2/3 phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer.
For research use only. We do not sell to patients.
- CAS No.: 325465-93-8
- Formula: C21H40NaO7P
- Molecular Weight:458.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
HY-107614
1-Oleoyl lysophosphatidic acid sodium -
HY-16039
AM095 -
HY-13285
Ki16425 -
HY-108496
Sphingosine-1-phosphate -
HY-16040
AM095 free acid -
HY-107615
TC LPA5 4 -
HY-107614R
1-Oleoyl lysophosphatidic acid sodium (Standard) -
HY-107616
H2L5186303 -
HY-100619
BMS-986020 -
HY-18641
Ki16198 -
HY-139853
BMS-986278 -
HY-15277
AM966
Biological Activity
Description
In Vitro
1-Oleoyl lysophosphatidic acid sodium competitively inhibits the activity of purified bovine serum lysophospholipase D (lysoPLD) in spectrophotometry and fluorescence analysis assays, with Ki values of 9.6 and 1.2 μM[1].
1-Oleoyl lysophosphatidic acid sodium (GMP) (400 nM-10 μM) induces concentration-dependent transient elevation of [Ca2+]i in primary rat and rabbit osteoclasts. Approximately 400 nM of the reagent elicits responses in 50% of the cells, and this response is mediated by Gi/o-coupled LPA1/3 receptors[3].
1-Oleoyl lysophosphatidic acid sodium (GMP) (5 μM) induces sustained retraction of lamellipodia and disrupts the peripheral actin belt in primary rat osteoclasts via a pathway involving Rho-associated kinases[3].
1-Oleoyl lysophosphatidic acid sodium (0-5 μM; 3-18 h) enhances the survival rate of primary rat osteoclasts, inhibits the apoptosis of primary rat osteoclasts, and induces the nuclear translocation of NFATc1 in primary rabbit osteoclasts via the Gi/o-coupled LPA1 receptor pathway[3].
1-Oleoyl lysophosphatidic acid sodium (5 μM; 5 min) induces mild ERK1/2 phosphorylation via a MEK1/2-dependent pathway in RAW 264.7-derived osteoclast-like cells[3].
1-Oleoyl lysophosphatidic acid sodium (0-10 μM; 0-96 h) induces delayed phosphorylation of Smad2 and Smad3 and subsequent expression of α-smooth muscle actin in human adipose tissue-derived mesenchymal stem cells via LPA receptor-dependent and Smad2/3-dependent signaling pathways[4].
1-Oleoyl lysophosphatidic acid sodium (5 μM; 0-48 hours, 4 days) induces the expression of α-smooth muscle actin in human adipose tissue-derived mesenchymal stem cells by stimulating autocrine TGF-β1 secretion and subsequent Smad2 activation[4].
1-Oleoyl lysophosphatidic acid sodium (0-20 μM; 0-48 h) induces the expression and secretion of stromal cell-derived factor-1 (SDF-1) in human adipose tissue-derived mesenchymal stem cells in a dose- and time-dependent manner via LPA receptor-dependent and TGF-β1-dependent signaling pathways[4].
1-Oleoyl lysophosphatidic acid sodium (5 μM; 4 days) induces the differentiation of human adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells (which express α-smooth muscle actin and calmodulin, but not smooth muscle myosin heavy chain)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW 264.7-derived osteoclast-like cells
-
Concentration:5 μM
-
Incubation Time:5 min
-
Result:Induced a small but significant increase in phospho-ERK1/2 levels.
Had effect blocked by 10 μM U0126.
-
Cell Line:human adipose tissue-derived mesenchymal stem cells (hADSCs)
-
Concentration:0-10 μM (dose-response); 5 μM (time-course); 5 μM (Ki16425 pre-incubation group); 10 μM (Ki16425)
-
Incubation Time:4 days (dose-response); 3-96 hours (time-course); 4 days (Ki16425 pre-incubation group)
-
Result:Increased α-SMA expression dose-dependently, with maximal increase at 5 μM after 4 days.
Increased α-SMA expression starting 48 hours after 5 μM treatment, with maximal levels at 96 hours.
Completely abolished the 5 μM-induced α-SMA expression when pre-incubated with 10 μM Ki16425.
-
Cell Line:human adipose tissue-derived mesenchymal stem cells (hADSCs)
-
Concentration:5 μM (time-course); 5 μM (Ki16425 pre-incubation group); 10 μM (Ki16425); 10 μM (SIS3); siRNA transfection (Smad2/3); adenoviral Smad7 expression
-
Incubation Time:0-96 hours (time-course); 4 days (inhibitor/siRNA/adenovirus groups)
-
Result:Induced delayed phosphorylation of Smad2 and Smad3, with maximal levels at 48 hours, sustained through 96 hours.
Completely abolished Smad2/3 phosphorylation when pre-incubated with 10 μM Ki16425.
Completely abrogated 5 μM-induced α-SMA expression and corresponding Smad phosphorylation after siRNA-mediated knockdown of Smad2 or Smad3.
Attenuated 5 μM-induced α-SMA expression and Smad3 phosphorylation (but not Smad2 phosphorylation) when pre-incubated with 10 μM SIS3.
Abrogated 5 μM-induced α-SMA expression and Smad2/3 phosphorylation after adenoviral overexpression of Smad7.
-
Cell Line:human adipose tissue-derived mesenchymal stem cells (hADSCs)
-
Concentration:5 μM
-
Incubation Time:4 days
-
Result:Increased expression of α-SMA and calponin in hADSCs.
Did not induce expression of smooth muscle myosin heavy chain (SM-MHC).
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (9-week-old male, 250-300 g)[2]
-
Dosage:0.4 μg/5 μL; 2 μg/5 μL
-
Administration:i.c.v.; single injection
-
Result:Reduced time spent in open arms by approximately 89% (2 μg dose, elevated plus-maze novelty condition); showed no significant effect on time spent in open arms (0.4 μg dose, elevated plus-maze novelty condition).
Reduced locomotor activity (crossings) by approximately 40% (2 μg dose, open-field test novelty condition); showed no significant effect on locomotor activity (0.4 μg dose, open-field test novelty condition).
Increased locomotor activity by approximately 180% (2 μg dose, open-field test habituation condition); showed no significant effect on locomotor activity (0.4 μg dose, open-field test habituation condition).
Reduced the percentage of rats that first entered the novel arm to chance levels (both doses, Y maze test); significantly reduced total time spent in the novel arm (0.4 μg dose, Y maze test); showed a near-significant reduction in total time spent in the novel arm (p=0.0558, 2 μg dose, Y maze test).
Increased immobility time by 75% (0.4 μg dose, forced swimming test); increased immobility time by 120% (2 μg dose, forced swimming test).
Increased c-Fos immunoreactivity in the dorsal periaqueductal gray matter (DPAG) by 94% (2 μg dose).
Chemical Information
-
CAS No. 325465-93-8
-
Molecular Weight 458.50
-
Formula C21H40NaO7P
-
SMILES
CCCCCCCC/C=C\CCCCCCCC(OC[C@@H](O)COP(O)(O[Na])=O)=O
-
Synonyms
1-Oleoyl-sn-glycero-3-phosphate sodium (GMP); 1-Oleoyl-LPA sodium (GMP)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Liu XW, et al. Inhibition of lysophospholipase D activity by unsaturated lysophosphatidic acids or seed extracts containing 1-linoleoyl and 1-oleoyl lysophosphatidic acid. J Agric Food Chem. 2007;55(21):8717-8722. [Content Brief]
[2]. Castilla-Ortega E, et al. 1-Oleoyl lysophosphatidic acid: a new mediator of emotional behavior in rats. PLoS One. 2014;9(1):e85348. Published 2014 Jan 7. [Content Brief]
[3]. Lapierre DM, et al. Lysophosphatidic acid signals through multiple receptors in osteoclasts to elevate cytosolic calcium concentration, evoke retraction, and promote cell survival. J Biol Chem. 2010;285(33):25792-25801. [Content Brief]
[4]. Jeon ES, et al. Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells. Stem Cells. 2008;26(3):789-797. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
1-Oleoyl lysophosphatidic acid sodium (GMP) Related Classifications
HY-107614G Related Classifications
Powered by Bioz
Keywords
- 1-Oleoyl lysophosphatidic acid sodium (GMP)
- 325465-93-8
- 1-Oleoyl-sn-glycero-3-phosphate sodium (GMP)
- 1-Oleoyl-LPA sodium (GMP)
- LPL Receptor
- ROCK
- TGF-beta/Smad
- TGF-β Receptor
- bioactive lipid signaling molecule
- anxiety
- depression
- ovarian cancer
- osteoclasts
- mesenchymal stem cells
- Wistar rats
- Inhibitor
- inhibitor
- inhibit